Chris Giordano
President and CEO, 10X Therapeutics
Replay available
Tenax Therapeutics, Inc. (TENX) Q3 2025 Earnings Call
Tenax Therapeutics, Inc. (NASDAQ: TENX) Q3 2025 earnings conference call, held 2025-11-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Stuart Ridge
Chief Medical Officer, 10X Therapeutics
Dr. Sanjeev Shah
Director, HFpEF Program, Northwestern University Feinberg School of Medicine
Dr. Barry Borlaug
Professor of Medicine and Cardiology, Mayo Clinic
Dave Reisinger
Analyst, Lee Ring Partners
Yasmine Rahimi
Analyst, Piper Sandler
Matt Fitts
Analyst, William Blair
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Tenax Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:06.178 Good afternoon, and welcome to the 10X Therapeutics virtual KOL call. 00:00:06.178 -- 00:00:10.203 At this time, all participants are in a listen-only mode. 00:00:10.203 -- 00:00:14.148 Should you need assistance, please signal a conference specialist by pressing the star 00:00:14.148 -- 00:00:16.430 key followed by zero. 00:00:16.430 -- 00:00:21.456 A question and answer session will follow the KOL panel discussion. 00:00:21.456 -- 00:00:26.742 To ask a question, you may press star, then one on your touchtone phone. 00:00:26.742 -- 00:00:31.030 To withdraw your question, please press star, then two. 00:00:31.030 -- 00:00:34.473 Please note, today's call is being recorded. 00:00:34.473 -- 00:00:39.618 I'd now like to turn the call over to Chris Giordano, President and CEO of 10X 00:00:39.618 -- 00:00:43.119 Therapeutics. Please go ahead. 00:00:43.521 -- 00:00:48.806 Thank you, Betsy, and welcome everyone to an in-depth discussion of the science 00:00:48.806 -- 00:00:53.710 behind 10X's ongoing development program in PHF-PET. 00:00:53.710 -- 00:00:55.912 We're developing TNX-103, 00:00:55.912 -- 00:01:01.201 an oral formulation of levocimendin, which we believe has the potential to to be a first-in-class 00:01:01.201 -- 00:01:03.922 treatment for PHHPAC. 00:01:04.104 -- 00:01:09.109 TNX103 is currently in late stage development in the phase three level study 00:01:09.109 -- 00:01:14.012 with top line data expected in the second half of 2026, 00:01:14.115 -- 00:01:19.160 and also level two, a global phase three study on track to initiate this 00:01:19.160 -- 00:01:20.801 year. 00:01:20.801 -- 00:01:26.267 TNX is not alone in focusing on patients with the most common form of PH 00:01:26.267 -- 00:01:31.645 for which no drug is approve...